Is Clearance of ctDNA an Acceptable Surrogate End Point?

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.